185 related articles for article (PubMed ID: 30425069)
81. High-risk smoldering myeloma: Perspective on watchful monitoring.
Leng S; Lentzsch S
Semin Oncol; 2016 Dec; 43(6):697-699. PubMed ID: 28061989
[TBL] [Abstract][Full Text] [Related]
82. New agents and approaches in the treatment of multiple myeloma.
Anderson KC
Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
[No Abstract] [Full Text] [Related]
83. [Multiple myeloma].
Abe M; Miki H; Nakamura S
Rinsho Ketsueki; 2016 Mar; 57(3):260-9. PubMed ID: 27076236
[TBL] [Abstract][Full Text] [Related]
84. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
85. Role of new treatment approaches in defining treatment goals in multiple myeloma--the ultimate goal is extended survival.
Durie BG
Cancer Treat Rev; 2010 May; 36 Suppl 2():S18-23. PubMed ID: 20472184
[TBL] [Abstract][Full Text] [Related]
86. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
87. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
[TBL] [Abstract][Full Text] [Related]
88. [Smoldering multiple myeloma].
Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
[TBL] [Abstract][Full Text] [Related]
89. Multiple myeloma.
Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
[TBL] [Abstract][Full Text] [Related]
90. Advances in the management of asymptomatic myeloma.
Mateos MV
Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868
[TBL] [Abstract][Full Text] [Related]
91. Update on proteasome inhibitors in multiple myeloma.
Richardson PG
Clin Adv Hematol Oncol; 2014 Mar; 12(3):179-81. PubMed ID: 24927266
[No Abstract] [Full Text] [Related]
92. Smoldering multiple myeloma.
Gao M; Yang G; Kong Y; Wu X; Shi J
Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
[TBL] [Abstract][Full Text] [Related]
93. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
[TBL] [Abstract][Full Text] [Related]
94. Daratumumab for the Treatment of Multiple Myeloma.
Plesner T; Krejcik J
Front Immunol; 2018; 9():1228. PubMed ID: 29915586
[TBL] [Abstract][Full Text] [Related]
95. Smoldering multiple myeloma: present position and potential promises.
Tageja N; Manasanch EE; Korde N; Kwok M; Mailankody S; Bhutani M; Roschewski M; Landgren O
Eur J Haematol; 2014 Jan; 92(1):1-12. PubMed ID: 24112232
[TBL] [Abstract][Full Text] [Related]
96. Researchers debate best use of stem cell transplants in patients with multiple myeloma.
Rowan K
J Natl Cancer Inst; 2009 Dec; 101(23):1608-11. PubMed ID: 19910555
[No Abstract] [Full Text] [Related]
97. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Khan R; Dhodapkar M; Rosenthal A; Heuck C; Papanikolaou X; Qu P; van Rhee F; Zangari M; Jethava Y; Epstein J; Yaccoby S; Hoering A; Crowley J; Petty N; Bailey C; Morgan G; Barlogie B
Haematologica; 2015 Sep; 100(9):1214-21. PubMed ID: 26022710
[TBL] [Abstract][Full Text] [Related]
98. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
Kyle RA; Remstein ED; Therneau TM; Dispenzieri A; Kurtin PJ; Hodnefield JM; Larson DR; Plevak MF; Jelinek DF; Fonseca R; Melton LJ; Rajkumar SV
N Engl J Med; 2007 Jun; 356(25):2582-90. PubMed ID: 17582068
[TBL] [Abstract][Full Text] [Related]
99. The difficult business of assessing new therapies for smouldering multiple myeloma.
Zonder JA
Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
[No Abstract] [Full Text] [Related]
100. New strategies for MGUS and smoldering multiple myeloma.
Kyle RA
Clin Adv Hematol Oncol; 2004 Aug; 2(8):507, 509. PubMed ID: 16163229
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
